Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma.
Sonneveld P, Zweegman S, Cavo M, Nasserinejad K, Broijl A, Troia R, Pour L, Croockewit S, Corradini P, Patriarca F, Wu K, Droogendijk J, Bos G, Hajek R, Teresa Petrucci M, Ypma P, Zojer N, Minnema MC, Boccadoro M.
Sonneveld P, et al. Among authors: troia r.
Hemasphere. 2022 Sep 30;6(10):e786. doi: 10.1097/HS9.0000000000000786. eCollection 2022 Oct.
Hemasphere. 2022.
PMID: 36204691
Free PMC article.